Docoh
Loading...

CRNX Crinetics Pharmaceuticals

GRANT
Utility
Somatostatin modulators and uses thereof
30 Nov 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee Kim, Yunfei Zhu
Filed: 19 May 20
APP
Utility
Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists and Uses Thereof
5 Aug 21
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon HAN, Yunfei ZHU, Sun Hee KIM, Jian ZHAO, Shimiao WANG
Filed: 8 Feb 21
GRANT
Utility
Somatostatin modulators and uses thereof
27 Jul 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee Kim, Yunfei Zhu
Filed: 16 Sep 19
APP
Utility
Somatostatin Modulators and Uses Thereof
10 Jun 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian ZHAO, Sangdon HAN, Sun Hee KIM, Shimiao WANG, Yunfei ZHU
Filed: 26 Oct 20
GRANT
Utility
Somatostatin modulators and uses thereof
8 Jun 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Yunfei Zhu, Shimiao Wang, Sangdon Han, Sun Hee Kim
Filed: 24 Jul 18
APP
Utility
Process of Making Somatostatin Modulators
25 Mar 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jayachandra P. REDDY, Mahmoud MIRMEHRABI, Madhukar KOTA, Uttam DASH, Jian ZHAO, Yunfei ZHU
Filed: 9 Dec 20
APP
Utility
Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof
18 Feb 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian ZHAO, Yunfei ZHU, Shimiao WANG, Mi CHEN, Joseph PONTILLO
Filed: 10 Aug 20
APP
Utility
Somatostatin Modulators and Uses Thereof
11 Feb 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian ZHAO, Shimiao WANG, Yunfei ZHU
Filed: 11 Feb 19
GRANT
Utility
Process of making somatostatin modulators
12 Jan 21
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jayachandra P. Reddy, Mahmoud Mirmehrabi
Filed: 3 Oct 19
APP
Utility
Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists and Uses Thereof
6 Jan 21
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon HAN, Yunfei ZHU, Sun Hee KIM, Jian ZHAO, Shimiao WANG
Filed: 15 Jul 20
GRANT
Utility
Somatostatin modulators and uses thereof
28 Dec 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Shimiao Wang, Yunfei Zhu
Filed: 11 Dec 19
APP
Utility
Somatostatin Modulators and Uses Thereof
9 Sep 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee KIM, Yunfei ZHU
Filed: 18 May 20
GRANT
Utility
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
7 Sep 20
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao
Filed: 12 Dec 19
APP
Utility
Melanocortin SUBTYPE-2 Receptor (MC2R) Antagonists and Uses Thereof
8 Jul 20
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon HAN, Yunfei ZHU, Sun Hee KIM, Jian ZHAO
Filed: 12 Dec 19
APP
Utility
Somatastatin Modulators and Uses Thereof
1 Jul 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian ZHAO, Yunfei ZHU, Shimiao WANG, Sangdon HAN, Sun Hee KIM
Filed: 23 Jul 18
GRANT
Utility
Somatostatin modulators and uses thereof
29 Jun 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon Han, Sun Hee Kim, Yunfei Zhu
Filed: 16 Sep 19
APP
Utility
Somatostatin Modulators and Uses Thereof
17 Jun 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian ZHAO, Sangdon HAN, Sun Hee KIM, Shimiao WANG, Yunfei ZHU
Filed: 11 Dec 19
GRANT
Utility
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
30 Mar 20
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang
Filed: 26 Aug 19
GRANT
Utility
Somatostatin modulators and uses thereof
23 Mar 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Jian Zhao, Shimiao Wang, Yunfei Zhu
Filed: 7 May 19
APP
Utility
Somatostatin Modulators and Uses Thereof
18 Mar 20
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Sangdon HAN, Sun Hee KIM, Yunfei ZHU
Filed: 16 Sep 19
Patents are sorted by USPTO publication date, most recent first